Fig. 2: Clinical associations of the master regulatory lncRNAs. | Nature Communications

Fig. 2: Clinical associations of the master regulatory lncRNAs.

From: LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation

Fig. 2: Clinical associations of the master regulatory lncRNAs.The alternative text for this image may have been generated using AI.

Boxplots show significant differential expression of MIR200CHG (a), AC104083.1 (b), and LINC00578 (c) between the MSS/EMT subtype and the non-MSS/EMT subtypes in the TCGA cohort (n = 54 samples for MSS/EMT, n = 43 samples for MSS/TP53-, n = 44 samples for MSS/TP53+, n = 38 samples for MSI). P-values were based on two-sided Wilcoxon rank-sum tests. Boxplots show significant associations between the expression of MIR200CHG (d), AC104083.1 (e), and LINC00578 (f) with tumor (T) stage (n = 8 samples for T1, n = 35 samples for T2, n = 94 samples for T3, n = 41 samples for T4). P-values were based on One-way ANOVA. g The univariate Cox regression analysis of lncRNAs and typical clinical factors in the TCGA cohort (n = 177 samples, Wald tests, **(MIR200CHG) P = 0.0031, ***(Stage) P = 0.00036, ***(M stage) P = 0.00012). h Patients with lower MIR200CHG expression had significantly worse overall survival (n = 177 samples, log-rank test). Boxes in all box-plots extend from the 25th to the 75th percentile and the lines indicate the median. The whiskers are drawn to the 5th and the 95th percentile.

Back to article page